Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Guggenheim Downgrades Albireo Pharma to Neutral

Guggenheim Downgrades Albireo Pharma to Neutral

Guggenheim analyst Seamus Fernandez downgrades Albireo Pharma (NASDAQ:ALBO) from Buy to Neutral.

byBenzinga Newsdesk

January 11, 2023

1 minute read

Guggenheim analyst Seamus Fernandez downgrades Albireo Pharma (NASDAQ:ALBO) from Buy to Neutral.

Analyst Ratings

Analyst Ratings for First Solar

By Benzinga Insights

June 26, 5:01 PM

Analysts have provided the following ratings for First Solar (NASDAQ:FSLR) within the last quarter: Bullish Somewhat Bullish Indifferent…

FSLR

News

‘Evidence Shows AI-Driven Companies Are Buying Up Gaming GPUs’ – Tom’s Hardware

By Happy Mohamed

August 1, 1:01 PM

https://www.tomshardware.com/news/evidence-shows-ai-driven-companies-are-buying-up-gaming-gpus Demand for GPUs is unquestionably ramping up again as prices eclipse $70,000 per GPU in some China

News

‘Oncore And Radware Partnership: Revolutionizing The Digital Transformation Landscape’ – Blog Post

By Happy Mohamed

February 24, 10:24 AM

https://blog.radware.com/all/radware-partner-insights/2023/02/oncore-and-radware-partnership-revolutionizing-the-digital-transformation-landscape/ The digital transformation landscape is rapidly changing, and businesses

RDWR